ArticleScientific reports2026
Immunogenomic classification reveals prognostic immune signatures in pediatric solid and hematological tumors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The immune features in pediatric tumor are poorly explored. To characterize immune features of pediatric cancer, we performed an immunogenomic analysis of public database (TARGET) for pediatric solid tumor (PST) (n = 423) and pediatric hematological tumor (PHT) (n = 2302). We clustered PST and PHT samples into 5 subtypes (S1-S5) and 4 subtypes (H1-H4), respectively, based on immune features. In the PST cohort, cluster S1 with elevated expression of Wound_CSR (fibroblast core serum response in wound healing) and B cell signatures exhibited the worst overall survival. Conversely, cluster S4 (HR = 0.378, 95% CI: 0.24–0.59, P-value < 0.001) with down-regulated expression of these features was associated with prolonged survival. We also validated the prognostic significance of the S4 immune subtype in an independent neuroblastoma cohort from the ZJUCH (n = 127), which demonstrated favorable patient outcomes. In the PHT cohort, we observed that the relationships between immune clusters and prognosis differed between FLT3-ITD mutation-positive AML (AML-1) and FLT3-ITD mutation-negative AML (AML-2). In AML-1, cluster H2 featured upregulated infiltration of neutrophils, monocytes and antigen processing signatures, possibly leading to the worst overall survival. While in AML-2, cluster H2 exhibited a favorable outcome. The study highlights the potential of immune features as biomarkers for prognosis and treatment planning in pediatric cancers and provides novel insights into their immunological landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.